Exploring the Role of Pharmacogenomics in Personalized Cancer Therapy

Unraveling Genetic Influences on Drug Response for Tailored Cancer Treatments

Abstract

This study explores the role of pharmacogenomics in developing personalized cancer therapies. We analyzed genetic variations in key metabolic enzymes and drug transporters in cancer patients and correlated these with treatment outcomes. Our findings demonstrate that specific genetic polymorphisms significantly influence the efficacy and toxicity of chemotherapeutic agents. By tailoring drug selection and dosing based on a patient's genetic profile, personalized cancer therapy can maximize therapeutic benefits while minimizing adverse effects. This research underscores the importance of integrating pharmacogenomics into clinical practice to enhance the precision and effectiveness of cancer treatment.